BIIBBiogen
Is the price fair?
Neither cheap nor expensive: modest expectations priced in, but at the top of its own P/E range and rich vs its sector.
Priced for ~1% a year FCF growth. The price bakes in little to no growth.
Expensive vs its own history: P/E 44.5 vs a 16.8 median over 41 quarters (+166% vs median).
Sector median 25.1× across 135 covered peers. EV/EBIT counts debt as part of the price, so a cash-rich and a borrowed company can be compared on the same footing.
Unless marked, from derived, as of Jun 30, 2026.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What BIIB's price assumes
Biogen trades at 44.5× earnings against 40.0× for the median Drug Manufacturers - General name, more expensive than its own group.
Trailing P/E · Drug Manufacturers - General median 40.0 · 1.11× the median: the market pays up for this one
- Price / sales
- 3.69
Price / sales · today's price, trailing year to Jun 30, 2026
- Free cash flow yield
- 7.3%
Free cash flow yield · Drug Manufacturers - General median 5.5%
- Growth the price implies
- +0.66%
Growth the price implies · The price pays for +0.66% free cash flow growth a year for a decade; the business has delivered +33% a year over the last three.
Details›
- Price / booktoday's price, trailing year to Jun 30, 2026
- 1.97
- EV / EBITtoday's price, trailing year to Jun 30, 2026
- 43.4
- EV / salestoday's price, trailing year to Jun 30, 2026
- 4.37
- Healthcare median P/E503 names
- 27.9
- Drug Manufacturers - General median P/E16 names
- 40.0
- Free cash flow, trailing twelve months
- $2.70B
- Market capitalisation147.8 million shares, counted Jul 27, 2026
- $37.1B
- 3-year revenue growth
- +0.19%
- 3-year free cash flow growth
- +33%
| Method | Per share |
|---|---|
| What its own history would imply | not meaningful, 44.5× today against a 16.8× median |
| 52-week range | $143.00 – $253.90 |
| Today | $250.76 |
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
What is it worth?
Today's price against what its own multiples, its cash flow and your growth assumption say it is worth.
Against its own past
Its multiples now against their own history, and how much of the price move came from earnings rather than the multiple.
Drug Manufacturers, General
The closest names by size in the same industry